Skip to main content
Clinical Trials/CTRI/2018/10/015943
CTRI/2018/10/015943
Completed
未知

COMPARATIVE STUDY TO ASSESS THE EFFICACY AND COSTEFFICIENCY OF IMMUNOLOGICALLY- TARGETED LOW DOSERITUXIMAB PROTOCOL WITH THE CONVENTIONALRHEUMATOID ARTHRITIS PROTOCOL IN SIGNIFICANT PEMPHIGUS

DEPARTMENT OF DERMATOLOGY0 sites23 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: L100- Pemphigus vulgarisHealth Condition 2: L100- Pemphigus vulgaris
Sponsor
DEPARTMENT OF DERMATOLOGY
Enrollment
23
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
March 31, 2020
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • PATIENTS OF PEMPHIGUS VULGARIS OR PEMPHIGUS FOLIACEOUS IN THE ABOVE MENTIONED AGE GROUP WITH SIGNIFICANT CLINICAL DISEASE WITH PDAI( PEMPHIGUS DISEASE ACTIVITY INDEX) SCORE \>15 AND WHO ARE WILLING FOR MONTHLY FOLLOW UP VISITS FOR 12 MONTHS.

Exclusion Criteria

  • PATIENTS WITH ACTIVE OR LATENT INFECTIONS LIKE HEPATITIS, TB OR SEPSIS.PREGNANT AND LACTATING FEMALES, PATIENTS WITH KNOWN CARDIAC ABNORMALITIES OR ARRHYTHMIA, SEVERELY DECREASED BONE MARROW FUNCTIONS, KNOWN HYPERSENSITIVITY TO MURINE PROTEINS OR ORAL CORTICOSTEROIDS. PATIENTS WHO HAVE RECEIVED RITUXIMAB IN PRECEDING 12 MONTHS OR DEXAMETHASONE PULSE THERAPY IN PRECEDING 3 MONTHS WILL ALSO BE EXCLUDED.

Outcomes

Primary Outcomes

Not specified

Similar Trials